The biopharma sector has seen incredible growth in recent decades, with growth the major long-term trend. Total annual revenue has increased from about $4.4 billion in 1990 to now about $275 billion, an increase of 6,250 percent, with biopharmaceuticals now more than 25 percent of the total pharmaceutical market. For over two decades, the biopharmaceutical manufacturing industry has created a body of industrial knowledge and institutional experience. The sector can be considered mature, and the trends relatively stable. This can be good for future planning, and it can allow time for things like novel bioprocessing technologies to shake out glitches as they make it through the R&D and the regulatory pipeline.